Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Marker Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $25,000,000 of shares of our common stock (effective 2022-12-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Lincoln Park Capital Fund, LLC
- Value
- up to $25,000,000 of shares of our common stock
- Effective
- 2022-12-12
Exact text from the filing
On December 12, 2022, Marker Therapeutics, Inc., a Delaware corporation referred to herein as we, us, our or the Company, entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over the 24-month term beginning on the Commencement Date (as defined below).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Marker Therapeutics, Inc. entered into Registration Rights Agreement with Lincoln Park Capital Fund, LLC (effective 2022-12-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Lincoln Park Capital Fund, LLC
- Effective
- 2022-12-12
Exact text from the filing
Concurrently with entering into the Purchase Agreement, we also entered into a registration rights agreement with Lincoln Park, or the Registration Rights Agreement, pursuant to which we agreed to register the sale of the shares of our common stock that have been and may be issued to Lincoln Park under the Purchase Agreement pursuant to a Registration Statement on Form S-1, or the Registration Statement.
View on SEC.gov